Kornimate/medical-research-clean huggingface dataset:
prevalence of lower and upper incisor periodontal phenotypes and risk indicators.

Conditions: Gingiva; Phenotype

Summary: the determination of the periodontal phenotype is an essential part of the periodontal diagnostic process, which must guide not only treatment but also prognosis (kim et al. 2020). this determination is based on the clinical assessment of 3 individual variables: gingival height/thickness and alveolar bone cortical thickness. although these anatomical characteristics are genetically determined, they are also influenced by numerous acquired, endogenous or exogenous factors that can act at a general and/or local level. the periodontal phenotype is therefore specific to an individual and its 3 components vary over time according to the dental sectors and sites of each individual. for example, the morphology of this phenotype varies according to whether the gingiva is thick or thin, high or reduced, and the bone cortex is thick or thin, with all possible combinations. clinicians need to know the distribution of these different types of phenotypes, particularly in the aesthetic areas they are concerned with, in order to better identify the most fragile ones in the face of the multiple daily stresses to which the periodontium may be subjected: muscular force, dental plaque, oral hygiene manoeuvres, parafunctionality, dental procedures.... however, studies on the prevalence of the periodontal phenotype are limited and mainly concern asian, indian and american populations, with very few studies on european populations. main objective: to assess the prevalence of periodontal phenotypes in the upper and lower incisors of french subjects, according to tooth type and at the individual level. secondary objective: identification of potential risk indicators in relation to the type of periodontal phenotype."


Eligibility criteria:
inclusion criteria: * age (18 years old or older), * dental student on the university hospitals of nice and nancy. * social security affiliate. * systemically healthy. * healthy and intact periodontium. * informed consent. exclusion criteria: * pregnancy. * under any regular medical treatment. * active periodontal disease. * enduring orthodontic treatment. * periodontal surgery in the mandibulary anterior region. * non consent patient. * patient under judgment trials.
oral pyrophosphate absorption in pxe disease

Conditions: Pseudoxanthoma Elasticum

Summary: pyrophosphate is an endogenous, non-toxic metabolite inhibiting soft tissue calcification. the aim of our study is to find optimal dosing and safety of oral disodium-ppi (na2h2ppi). absorption curves (pharmacokinetics), auc0-t, cmax and tmax for ppi and phosphate will be provided for healthy controls and pxe-patients both fasting and with standard meal intake.

phase ii oral capsulized disodium-ppi (na2h2ppi) powder absorption study in subjects with pxe (n=8-12) will be done in the ward of internal medicine of tampere university hospital and university medical center utrecht. after a 10-hour fast at 8.00 a.m. 30 mg/kg (first day) and 50 mg/kg (second day) capsulized dose of ppi will be given with 2 dl water. at 12.00 a.m. another capsulized 30 mg/kg (first day) or 50 mg/kg (second day) single dose of ppi with a standard mixed meal (lunch) will be given with 2 dl water at the time when a subject starts eating. plasma and urine sampling include plasma and spot urine electrolytes, creatinine, and pyrophosphate. plasma sampling will be done at 0, 15, 30, 60, 120 and 240 min after ingestion of ppi. urine spot sample will be taken at 0 and 240 min after ingestion of ppi. physical activity is restricted. side-effects will be recorded.

Eligibility criteria:
inclusion criteria: * adults (\>18 yrs) * clinically and genetically proven pxe * body mass index (bmi) 18,5-34,9 kg/m2 exclusion criteria: * special groups according to researchers' decision. * pregnancy * no effective contraception in females in child-bearing age.
the gp's role in cancer rehabilitation: a randomised, controlled study.

Conditions: HRQOL (Health Related Quality Of Life)

Summary: the aim of this study is to investigate the impact of a joint effort towards intensifying the collaboration and communication between hospital and general practice.

background in recent years an increasing focus has been on the unfulfilled needs of cancer patients for an individual rehabilitation taking into consideration the physical, psychological, social, economic, as well as work-related consequences of the cancer disease. furthermore, there is a great need for ongoing adjustments of the organisation and procurement of rehabilitation offers and for optimizing the continuity of care, especially regarding transfer between sectors. research question the aim of this study is to investigate whether a joint effort towards intensifying the collaboration and communication between hospital and general practice and encouraging the gp to take an active and prominent part in the rehabilitation process on actual patients has any effect on: 1. health related quality of life 2. the rehabilitation of cancer patients 3. the experience of continuity of care among cancer patients 4. how the gp act with regard to rehabilitation among cancer patients material and methods the study uses a randomised, controlled design and is carried out as a phd project. at vejle hospital approximately 1000 patients (500 in the intervention group and 500 in the control group) was included at the initiation of treatment. the intervention consists of an extended information routine from hospital to gp based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' gp to play a proactive role in the patients' rehabilitation course. the individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. the data will be obtained from public health registers and questionnaires to patients 6 and 14 months after the time of diagnosis (measuring health related quality of life, satisfaction with and use of rehabilitation activities, perceived continuity of care and satisfaction with their gp) and to gps after 12 months (measuring satisfaction with the information from the hospital and activities to meet the patients' rehabilitation needs).

Eligibility criteria:
inclusion criteria: * all new cancer patients receiving treatment, be it surgery, chemotherapy or radiation, at vejle hospital in the period of inclusion. exclusion criteria: * patients diagnosed more than 3 months earlier * patients younger than 18 * patients with non-melanoma skin cancer. * patients with recurrence of a previous cancer

Keywords: hrqol rehabilitation cancer patients general practice
assessment of the safety and performance of knee ligament supports in the context of a return to sport after sprain

Conditions: Knee Sprain (Mild); Knee Sprain (Moderate); Anterior Cruciate Ligament Tear

Summary: decathlon has developed kneemid500-strong700 products which are two medical devices designed to be used for sport resumption after mild (kneemid500) or moderate (kneestrong100) knee sprain or after an anterior cruciate ligament surgery. the difference between these devices is based on the strength of compression and the knee maintain. the objective of this multicentre study is to collect data on the related clinical complications and clinical outcomes of market-approved decathlon kneemid500-strong700 products to demonstrate safety and performance of these devices in a real-world setting.


Eligibility criteria:
inclusion criteria: * subject is aged ≥18 years old * subject has a recent mild (grade i) or moderate (grade ii) knee sprain or an acl surgery * the current condition of his/her knee allows the subject to resume usual physical activity * subject has been informed and is willing to sign an informed consent form * subject is willing to comply with protocol requirements and return to the study center for all clinical evaluations and required follow-up (18 weeks) * subject is affiliated to the french social security regime non-inclusion criteria: * subject has conditions that may interfere with his/her ability to understand protocol requirements, participate in scheduled visits, or provide his/her informed consent * subject has worn a support (knee brace or articulated orthosis) since his/her recent injury * subject has resumed regular physical activity since his/her recent injury * subject has any medical condition that could impact the study at investigator's discretion * subject has a known hypersensitivity or allergy to the components of the device (polyamide, elastane, elastodiene) * adult subject to a legal protection measure
only gonadotropin vs. letrozole combined gonadotropin stimulation in iui cycles

Conditions: Infertility Unexplained

Summary: the present randomized controlled study aims to investigate the effectiveness of a combined regimen of letrozole and gonadotropin with dose adjustments based on body mass index (bmi) compared to a conventional only gonadotropin regimen in intrauterine insemination (iui) cycles for couples experiencing unexplained infertility. the study was conducted at a tertiary university hospital's assisted reproductive technologies (art) center from january 2023 to january 2024. couples with unexplained infertility were enrolled based on comprehensive assessments, and randomization was performed based on national id (odd or even). the conventional only gonadotropin (cog) group received recombinant fsh based on body mass index (bmi), while the combined letrozole-gonadotropin (clg) group received letrozole followed by gonadotropin with dose adjustments based on bmi. ovulation induction and iui were performed according to standard protocols. clinical outcomes, gonadotropin consumption, and pregnancy rates were compared between groups. among 317 iui cycles, 131 couples with unexplained infertility were randomized (clg: 61, cog: 70). demographic parameters were similar between groups. the clg group had lower daily gonadotropin doses (67 ± 18 iu/d vs. 76 ± 11 iu/d, p=0.01) and total gonadotropin consumption (750 iu vs. 825 iu, p=0.01) with comparable ovulation and clinical pregnancy rates. the cog group exhibited higher multiple pregnancy rates, although not statistically significant (clg vs. cog; 1/61 vs. 3/70, p=0.4). the study suggests that the combined letrozole and gonadotropin regimen with bmi-based dose adjustments in iui cycles for unexplained infertility is associated with reduced gonadotropin consumption and potentially lower multiple pregnancy rates.


Eligibility criteria:
inclusion criteria: * couples with unexplained infertility * aged between 18-35 exclusion criteria: * male factor infertility * diminished ovarian reserve * patient refusion to participate

Keywords: unexplained infertility letrozole gonadotropin intrauterine insemination
hemodynamic performance in stentless heart valves

Conditions: Heart Valve Diseases

Summary: hypothesis: stentless bioprostheses will perform superior to stented bioprostheses in different hemodynamic and biomechanical parameters. the study will investigate turbulence, flow and aortic root movement in a stentless bioprosthesis and compare it to a stented bioprosthesis.


Eligibility criteria:
inclusion criteria: * over 65 years old * submitted for aortic valve surgery * no coronary surgery other than lima to lad exclusion criteria: * stentless valve implantation not possible * contraindications for mri scan

Keywords: stentless biological aortic heart valve prosthesis artificial
sleep study in adult patients with major sickle cell disease with paroxysmal nocturnal events

Conditions: Sickle Cell Disease

Summary: hypothesis is that the occurrence of nocturnal vaso-occlusive crisis (voc) and priapism in adults might be related to episodes of nocturnal desaturation secondary to a sleep apnea syndrome. investigator hypothesize that chronic biological consequences of obstructive sleep apnea (hypercoagulability, endothelial dysfunction ...) favour voc and acute manifestations (nocturnal desaturation) favour nocturnal voc. the confirmation of this hypothesis will lead investigator to propose a systematic screening of obstructive sleep apnea (osa) in patients with nocturnal voc. moreover, systematic treatment of osa in sickle cell patients could help significantly reduce the number and severity of nocturnal voc.


Eligibility criteria:
inclusion criteria: night voc group: * night voc ≥ 2 in the previous year * written informed consent daytime voc group: * voc no nocturnal * diurnal voc ≥ 2 in the previous year * written informed consent slightly symptomatic group: * no hospitalization for voc * written informed consent exclusion criteria: * taking opioids * taking medication that alters sleep (antidepressants, benzodiazepines ...) * known history of sleep apnea syndrome * known history of serious psychiatric disorder * recent vaso-occlusive crisis (within 3 weeks) * changes in background treatment (hydrea or exchange transfusions) in the past 12 months * inactive affiliation to social security * under legal protection * a female who is pregnant or breastfeeding * prisoners * emergency situation * refusing to participate in the study

Keywords: vaso-occlusive crisis obstructive sleep apnea priapism
is there a benefit to optimize heart failure (hf) treatment in aged over 80 year's old patients?

Conditions: Heart Failure

Summary: the purpose of this study is to determine if there is an interest to optimize hf (heart failure) management in patients over 80 years old. the primary objective is to assess the effect of hf (heart failure) optimized management (guidelines of the european society of cardiology (esc) on quality of life (qol) in aged over 80 year's old at 6 months.

aging population, and better management of various heart diseases including ischemic explain the growing up of incidence and prevalence of chronic heart failure. the aging of the population leads now to support services in cardiology and particularly in the units of heart failure in subjects over 80 years. it's a special population with several co-morbidities, in whom it is difficult to introduce all the recommended treatments with optimal doses. there is indeed a significant difference between the optimal doses of treatments tested in studies on heart failure and doses found on the orders of inpatients for hf (heart failure). unfortunately clinical trials on heart failure have recruited young patients, mean age 65 years. clinical studies in cardiology and particularly in heart failure recruit young subjects at the expense of seniors who are underrepresented in these studies. the investigators will compare two groups: the first one with an "optimized" management and the second one as "usual care". the primary endpoint will evaluate the quality of life at 6 months according to the scale of minnesota. secondary outcomes will be the quality of life at 12 months, quality of life measured by the sf 12 (to check what level is most suited to this population) at baseline, 6 months and one year, mortality at 12 months, the number of re-hospitalization and cardiovascular events at 12 months, new york health association (nyha) class (at baseline, 6 months and 12 months) and walking test for 6 minutes (at baseline, 6 months and 12 months). finally the investigators plan to conduct an analysis on the medical and economic interest of this support.

Eligibility criteria:
inclusion criteria: * aged over 80 year's old subjects * hospitalized for an acute heart failure * left ventricle ejection fraction ≤ 35% * evaluated life expectancy (seattle hf score) \> 1 year exclusion criteria: * dementia * does not understand french language * followed with an optimized management * with reduced mobility * recruited in another clinical trial or in a hf management network * ahf with curable aetiology : cardiovascular surgery for cabg or valvular replacement, angioplasty * mdrd \< 30 ml/min/1.73m²

Keywords: heart failure aged and over 80 clinical trial quality of life
impact of photobiomodulation bone healing following cystic enucleation

Conditions: Maxillary Cyst

Summary: a well-known issues confronted by oral and maxillofacial specialists are the osseous defects and dead spaces and how can be obliterated and augmented in the facial regions. unerupted tooth and bone loss after its removal, remaining roots and enucleation of cysts; all of which makes prosthetic rehabilitation and implant application more complicated

bone is undergoes remodeling via cycles of bone resorption and bone formation which is considered a mineralized connective tissue, an inflammatory immune reaction which is triggered by local injury which is thought to highly influence the outcome of the bone healing process. low-level laser therapy (lllt) is a form of phototherapy that involves the application of low power monochromatic and coherent light to areas of injuries and lesions. it has been shown to induce wound healing in non-healing bone defects . bone healing is a multidimensional process of reconstruction of the bone tissue with an overlapping timeline. because of the regeneration ability of the bone, bone defects can heal spontaneously under suitable physiological environmental conditions. the healing process of the bone defect is time consuming, and new bone generation takes place slowly because of diminished of blood supply to the defect site and insufficiency of calcium and phosphorus to strengthen and harden new bone. the low-level laser therapy (lllt) has a positive effect on bone tissue metabolism . moreover it is beneficial for the initial stages of alveolar bone healing and for further calcification; an experimental animal study in both diabetic and normal rats under histological observations and gene expression analyses have confirmed this when applied at a dose of 13.95 j/cm2 for 60 sec .

Eligibility criteria:
inclusion criteria: - patients (class i category according to american society of anesthesiologists) over 20 years and under 50 years of age, of either gender who are seeking cyst enucleation of painful intra-body maxillary cystic lesions 3 x 4 cm in size. exclusion criteria: * any systemic disease that interferes with bone healing, * patients with significant medical condition, * alcoholic individuals, * patients on drugs that affect the central nervous systems, * patients who reported the use of drugs that might interfere with pain sensitivity * pregnancy, * lactation
comparison of clinical parameters in chronic obstructive pulmonary disease patients and healthy individuals

Conditions: COPD (Chronic Obstructive Pulmonary Disease)

Summary: the investigators think that the functions of core stabilization muscles are different in chronic obstructive pulmonary disease (copd) patients than in healthy individuals. this muscle group plays an important role not only in stabilization but also in respiratory parameters. no study has been found investigating the functions of these muscles in this patient group. the investigators aimed to compare respiratory parameters, muscle parameters, exercise capacity, balance, quality of life, anxiety and depression levels in individuals with copd and healthy individuals.

individuals diagnosed with copd between the ages of 40-80 who applied to ankara etlik city hospital chest diseases polyclinic will be included in the study. healthy individuals will be between the ages of 40-80 who volunteered to participate in the study. data collection tools will be made by the same researchers. for calculating the sample size required for the study, a power analysis will be conducted using pilot data after evaluating 10 individuals with copd and 10 healthy adults.

Eligibility criteria:
inclusion criteria: inclusion criteria for individuals with copd: * being diagnosed with copd * being between the ages of 40-80 * being clinically stable (not having had an exacerbation in the last month) * being able to cooperate with the tests * not participating in any exercise training studies * being willing to participate in the study inclusion criteria for healthy individuals: * being between the ages of 40-80 * not having a known acute or chronic health problem that would prevent the performance of the tests or affect the performance of the tests * not participating in any exercise training program * being willing to participate in the study exclusion criteria: exclusion criteria for individuals with copd: * having other lung or lung involvement diseases other than copd * having uncontrolled hypertension, arrhythmia and a history of myocardial infarction in the last month, unstable angina, advanced heart failure and other cardiac instability conditions * being hemodynamically unstable * being on noninvasive mechanical ventilation (nimv) and long-term oxygen therapy (ltot) * having a history of neuromuscular disease, scoliosis, chest wall surgery * having pregnancy and malignancy * having orthopedic or surgical conditions that would prevent participation in tests * not willing to participate in the study exclusion criteria for healthy individuals: * having a known acute or chronic health problem that would prevent the performance of the tests or affect the performance of the tests * being pregnant * not willing to participate in the study

Keywords: copd exercise capacity muscle parameters
pilot project of forest bathing for promoting health

Conditions: Intellectual Disability

Summary: an exploratory trial using a cuasi-experimental design aimed to improve the quality of life of people with intellectual disabilities. the intervention consists of 11 consecutive sessions of forest bathing (one session per week), each one lasting about 2 hours. each session involves an easy walk through a forest area, interspersed with non-intrusive activities of contact with the surrounding nature aimed at fostering mindfulness and the use of the five senses. data were collected at baseline, post intervention, and 7 months of follow-up.


Eligibility criteria:
inclusion criteria: * adults with intellectual disability enrolled in a specific occupational center. * being informed about the study and having signed the informed consent document. exclusion criteria: * having stated their not willing to participate in the study